CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.
Antimicrobial resistance (AMR) is a critical global health challenge, requiring early and accurate detection of resistance ...
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
AZoLifeSciences on MSN16h
CRISPR Unlocks the Secrets of Flowering in PlantsProfessor and HHMI Investigator Zachary Lippman and his colleagues are exploring how non-coding DNA segments, known as ...
The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.
CRISPR epigenome editing successfully reactivates silenced genes in Prader-Willi Syndrome, highlighting potential for ...
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
Vontobel Holding Ltd. trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 11.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 15,068 shares of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback